India Pharma Outlook Team | Friday, 29 August 2025
MedGenome unveiled the first CNS Tumour Methylation Classifier Test in India, which is a futuristic diagnostic tool that can recognize and categorize the most initial 90+ kinds of brain tumors and central nervous system (CNS) tumors as well as precise subtypes.
This test has been conceptualized to bring in the clinical support advanced knowledge for treatment planning and individualized care. This remarkable innovation was presented at a precision oncology symposium held in Mumbai, co-hosted by MedGenome and Illumina, the world’s leading company in sequencing technologies for DNA.
The event had the attendance of about 200 oncologists, neurosurgeons, pathologists, and researchers. Brain and CNS tumours are among the least understood diseases and are difficult to diagnose. Traditional histology continues to be the backbone of diagnosis, however, MedGenome’s new test serves as an addition to these methods as it practically looks at the whole genome through DNA methylation profiling.
The method is capable of recognizing the chemical modifications that are spread all over the genome, and so it produces a unique tumour profile that is then compared with the world’s reference database for a precise classification.
Also Read: Containment Strategies in Pharma Facilities
On the occasion of launching the product, Dr. VL Ramprasad, CEO, MedGenome, said, “Every cancer is different in its own way, Whole genome methylation profiling is like a lens which makes the differences between these cancers clearer to us and thus helps us in choosing the most appropriate treatment.”
The developed test works exactly according to the World Health Organization’s 2021 guidelines and delivers results within 21 days. These results consist of the assignment of the WHO grade, genome-wide copy number profiling as well as the detection of the key gene alteration, which is a very important milestone in precision oncology in India.
